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Abstract
 
Previous pharmacologic and genetic studies have demonstrated a critical role for the low mo-
lecular weight GTP-binding protein RhoA in the regulation of cell-mediated killing by cyto-
toxic lymphocytes. However, a specific Rho family guanine nucleotide exchange factor (GEF)
that activates this critical regulator of cellular cytotoxicity has not been identified. In this study,
we provide evidence that the Rho family GEF, Vav-2, is present in cytotoxic lymphocytes,
and becomes tyrosine phosphorylated after the cross-linking of activating receptors on cyto-
toxic lymphocytes and during the generation of cell-mediated killing. In addition, we show
that overexpression of Vav-2 in cytotoxic lymphocytes enhances cellular cytotoxicity, and this
enhancement requires a functional Dbl homology and Src homology 2 domain. Interestingly,
the pleckstrin homology domain of Vav-2 was found to be required for enhancement of killing
through some, but not all activating receptors on cytotoxic lymphocytes. Lastly, although Vav
and Vav-2 share significant structural homology, only Vav is able to enhance nuclear factor of
activated T cells–activator protein 1–mediated gene transcription downstream of the T cell re-
ceptor. These data demonstrate that Vav-2, a Rho family GEF, differs from Vav in the control
of certain lymphocyte functions and participates in the control of cell-mediated killing by cyto-
toxic lymphocytes.
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Introduction
 
The low molecular weight GTP-binding proteins of the
Rac and Rho family of GTPases have been identified as
critical transducers of signals downstream of activating re-
 
ceptors on lymphocytes (1). The Dbl homology (DH)
 
1
 
domain-containing guanine nucleotide exchange factors
(GEFs) are a family of proteins that interact exclusively
with members of the Rho/Rac family of GTPases and pro-
mote GTP for GDP exchange (2). Members of this family
of proteins are widely expressed, and many of them can
promote tumor formation when overexpressed in either
their wild-type or oncogenic forms (2). In fact, Vav, which
is a Dbl family member, was identified due to its ability to
transform mouse fibroblasts (3, 4). The Vav protooncogene
is primarily expressed in hematopoietic cells and is among
the most extensively studied member of this family of pro-
teins (5, 6). It has been shown that Vav undergoes tyrosine
phosphorylation after the cross-linking of many activating
receptors on hematopoietic cells, including the TCR, B
cell receptor, FcR (7–10), and during the generation of
natural cytotoxicity (11). Tyrosine phosphorylation of Vav
is required for Vav GEF activity (12, 13), and inactivation
of the Vav Src homology 2 (SH2) domain inhibits recep-
tor-mediated tyrosine phosphorylation (14, 15). In addition
to the SH2 domain, Vav contains numerous other protein
 
subdomains including two SH3 domains, an NH
 
2
 
-terminal
calponin homology (CH) domain, an acidic region, a DH
domain followed by a pleckstrin homology (PH) domain, a
cysteine-rich region, and a proline-rich region (PR) (6).
The presence of so many protein subdomains in Vav sug-
gests that it has the ability to interact with many signaling
molecules.
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Abbreviations used in this paper: 
 
ADCC, antibody-dependent cellular
cytotoxicity; AP, activator protein; CH, calponin homology; DH, Dbl
homology; GEFs, guanine nucleotide exchange factors; NFAT, nuclear
factor of activated T cells; NRS, normal rabbit serum; PH, pleckstrin ho-
mology; PI3-K, phosphatidyl inositol 3-kinase; PR, proline-rich region;
PTKs, protein tyrosine kinases; SH, Src homology; WR, wild-type vac-
cinia virus. 
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Recently, Vav-2, a new member of this family of GEFs,
has been identified (16–18). Overall, these two proteins
share similar arrangements of their structural domains. In
addition, like Vav, tyrosine phosphorylation of Vav-2 is re-
quired for intrinsic GEF activity, and it was recently shown
that Vav-2 can be phosphorylated by Src family and Syk
family protein tyrosine kinases (PTKs) in vitro (18). How-
ever, whereas Vav has been found to undergo tyrosine
phosphorylation after stimulation through numerous lym-
phocyte activation receptors, receptor-mediated tyrosine
phosphorylation of Vav-2 has not been reported. Also, in
contrast to Vav, which is primarily expressed in hemato-
poietic cells, Vav-2 is more ubiquitously expressed (16, 17).
Moreover, whereas Vav acts as a GEF toward Rac-1, Rac-2,
and RhoG (12, 13, 18), Vav-2 displays GEF activity to-
ward RhoA subfamily members and RhoG (18). These
data provide an excellent view into the biochemical prop-
erties of these two Vav family GEFs. However, the identi-
fication of cell surface receptors that are linked to Vav-2
activation and the role that Vav-2 plays in the development
of receptor-initiated events remains unclear.
The generation of cell-mediated killing by NK cells re-
quires activation of proximal PTKs (19–21). We and others
have previously shown that Vav undergoes receptor-medi-
ated tyrosine phosphorylation after cross-linking of Fc
 
g
 
-
RIIIA on human NK cells and during the generation of nat-
ural cytotoxicity (10, 11). In addition, it has been shown that
Vav and one of its target molecules, Rac-1, regulate the
generation of cell-mediated killing by NK cells and CD8
 
1
 
CTLs (11, 22). Furthermore, inactivation of the RhoA
GTPase by pharmacologic or genetic approaches has been
shown to block the development of cellular cytotoxicity by
these two cell populations (11, 23). Therefore, the regula-
tion of cell-mediated killing by cytotoxic lymphocytes in-
volves receptor-mediated regulation of both Rac and Rho
GTPases. However, the identification of a Rho subfamily
GEF that is regulated by activating receptors in these cells
has not been identified.
Northern blot analysis has identified Vav-2 RNA in
lymphoid organs including the thymus and spleen (16, 17).
We therefore sought to determine: (a) if Vav-2 is present in
cytotoxic lymphocytes; (b) whether Vav-2 undergoes re-
ceptor-mediated tyrosine phosphorylation during the gen-
eration of cytotoxicity by these two cell types; (c) whether
Vav-2 can regulate the generation of cell-mediated killing;
and (d) what subdomains of Vav-2 are critical for its activ-
ity. To this end, we have found that Vav-2 is expressed in
cytotoxic lymphocytes and undergoes receptor-mediated
tyrosine phosphorylation after the cross-linking of activat-
ing receptors on cytotoxic lymphocytes and during the
generation of natural cytotoxicity. Also, although overex-
pression of Vav-2 in cytotoxic lymphocytes results in en-
hanced cellular cytotoxicity, Vav-2 mutants containing in-
activating mutations in the DH or SH2 domain cannot.
Moreover, we have found that the PH domain of Vav-2 is
required for its activation downstream of some but not all
activating receptors on cytotoxic lymphocytes. Lastly, in
contrast to Vav, Vav-2 is unable to regulate nuclear factor
 
of activated T cells (NFAT)–activator protein (AP)-1–
mediated gene transcription after TCR cross-linking. To-
gether, our data highlight Vav-2 as a regulatory molecule
for the development of cell-mediated killing by cytotoxic
lymphocytes.
 
Materials and Methods
 
Reagents, Cells, and Antibodies. 
 
Unless otherwise stated, all
chemicals were from Sigma-Aldrich. The Jurkat T cell line, anti-
CD3–producing hybridoma OKT3 (murine IgG2a), K562 ery-
throid leukemia cell line, HeLa epithelial cell line, and murine
mastocytoma cell line P815 were obtained from American Type
Culture Collection. Human NK cells and CD8
 
1
 
 T cells were
cloned and passaged as previously described (24). The long-term
melanoma-specific CTL line recognizing the G9
 
209
 
 peptide of the
melanoma-associated antigen gp100 was provided by E. Celis
(Mayo Clinic, Rochester, MN). Antibodies used in this study in-
cluded the anti-FLAG murine mAb FLAG-M2 (Sigma-Aldrich),
antiphosphotyrosine mAb 4G10 (Upstate Biotechnology), and
goat anti–mouse IgG F(ab
 
9
 
)
 
2
 
 (ICN Biochemicals). Anti-Fc
 
g
 
RI-
IIA mAb 3G8 and anti-CD3 mAb OKT3 were purified from as-
cites by affinity chromatography over protein A–agarose. Rabbit
polyclonal antiserum to Vav-1 was obtained after immunization
of rabbits with KLH-conjugated Vav peptide 566–593 (HGQD-
FAGTMKKDKLHRRAQDKKRNELGL, anti-Vav; Cocalico
Biologicals, Inc.). Two separate rabbit polyclonal antisera to Vav-2
were obtained by immunization of KLH-conjugated peptides de-
rived from Vav-2, amino acids 134–155 (TTENDDDVYR-
SLEELADEHDLG, anti–Vav-2.1), and amino acids 448–473
(EIIELLFHKMTDDPMNNKDVKKSHGK, anti–Vav-2.2). Both
anti–Vav-2 polyclonal rabbit sera were affinity purified using the
Sulfolink kit from Pierce Chemical Co. and the synthetic peptide
as per manufacturer protocol.
 
DNA Constructs and Recombinant Vaccinia Generation. 
 
The
recombinant vaccinia expressing FLAG-tagged Vav (F.Vav) has
been previously described (11). To obtain Vav-2 recombinant
vaccinia, the Vav-2 coding sequence was isolated by double di-
gestion with HindIII and NotI from a Vav-2 cDNA provided by
D.J. Kwiatkowski (Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA) (16) and then subcloned into the
pSHN11 vaccinia recombination substrate. The Vav-2 construct
was FLAG tagged using the previously described FLAG adaptor
(11). The fragment was then subcloned using standard molecular
biology techniques into similarly digested pCDNA3. All recom-
binant vaccinia viruses were produced via homologous recombi-
nation with the WR strain of virus as previously described (11).
Using the Site-Directed Mutagenesis kit (CLONTECH Labora-
tories Inc.) all of the mutations were obtained as previously de-
scribed (11). The single amino acid point mutations were gener-
ated using the pSHN11 selection oligonucleotide along with the
specific Vav-2 mutagenic oligonucleotides, Y213F/L217Q (5
 
9
 
-
GAGACCGAGGCCAAG
 
TTC
 
TACCGCACC
 
CAG
 
GAGGA-
CATTGAGAAG-3
 
9
 
), W503L (5
 
9
 
-GATATGAAGAGGAAG
 
CT
 
-
 
G
 
ATGGAGCAGTTTGAG-3
 
9
 
), and R698A (5
 
9
 
-GGGACCTA-
CCTGATG
 
GCG
 
GAGCGGCCTGCCGAG-3
 
9
 
). The Vav-2
TRUNC mutant was generated by introduction of a HindIII
site at amino acids 573/574 using the mutagenic oligonucleotide
(5
 
9
 
-GTGATACCTCCCTGC
 
AAGCTT
 
ACTTCTCCTGCA-
GAT-3
 
9
 
). The mutant was digested with HindIII to remove the
5
 
9
 
 coding sequence and religated, and a FLAG adaptor was
added. The nucleotides in bold represent the mutational changes 
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resulting in either amino acid changes or in the case of the
TRUNC mutant, the addition of a HindIII site.
 
Electroporation and Luciferase Assays. 
 
Jurkat T cells (10
 
7
 
) were
electroporated with 20 
 
m
 
g of pCDNA3 control vector, Vav-1, or
Vav-2-expressing vectors along with 10 
 
m
 
g of the pNFAT
 
3
 
–
luciferase construct as previously described (25). After 18–24 h of
incubation the cells were stimulated as indicated in the figure leg-
end and luciferase activity was measured as previously described
(25). The percentage of maximal NFAT activity was determined
by dividing the luciferase activity obtained in the absence or pres-
ence of stimulation, by that obtained by stimulation with PMA 
 
1
 
ionomycin. The maximum NFAT–AP-1 responses did not differ
significantly between transfection conditions. Protein expression
of the electroporated constructs was determined by immunopre-
cipitating F.Vav-1 and F.Vav-2 proteins from 2 
 
3
 
 10
 
6
 
 electropo-
rated cells using the anti-FLAG mAb, followed by anti-FLAG
immunoblotting.
 
Cytotoxicity Assays. 
 
The 
 
51
 
Cr-release assays were performed
as described previously (24). In all cases, spontaneous release did
not exceed 10% of maximum release. In redirected cytotoxicity
assays, NK clones and CD8
 
1
 
 T cell clones were only able to kill
the P815 target cell in the presence of anti-FcR or anti-CD3
mAb, respectively. Lytic units were calculated based on 20% cy-
totoxicity (26).
 
Ca
 
2
 
1
 
 Mobilization Assays. 
 
Changes in levels of intracellular
Ca
 
2
 
1
 
 of vaccinia-infected, Indo-1–loaded cells was assessed by
flow cytometer using a FACStar
 
®
 
 (Becton Dickinson) as previ-
ously described (27). In brief, Jurkat T cells were infected with
the indicated nonrecombinant (WR) or recombinant vaccinia vi-
rus for 2 h in a humidified 37
 
8
 
C incubator at a multiplicity of in-
fection of 10:1. For the last 30 min of the infection, the cells were
loaded with 5 
 
m
 
M Indo-1 (Calbiochem-Novabiochem). They
were then washed in PBS containing 1% BSA and resuspended in
RPMI-10 until analyzed. For analysis, the Indo-1–loaded Jurkat
T cells were incubated with either goat anti–mouse IgG F(ab
 
9
 
)
 
2
 
alone (as a baseline control) or a combination of anti-CD3 mAb
OKT3 (2.5 
 
m
 
g/ml) and goat anti–mouse IgG F(ab
 
9
 
)
 
2
 
. The sam-
ples were immediately analyzed by flow cytometry using a UV
laser for excitation with violet (390 nm) and blue (500 nm) fluo-
rescence emissions recorded. The data plots were generated using
the FlowJo software program (TreeStar Inc.).
 
Cell Stimulation and Immunoblot Analysis. 
 
In experiments an-
alyzing endogenous Vav and Vav-2 proteins, Vav and Vav-2
were specifically immunoprecipitated for 1–2 h from the cell ly-
sates of the indicated cell lines using either normal rabbit antise-
rum as a control or the specific anti-Vav or anti–Vav-2.1 rabbit
polyclonal antisera. In experiments involving viral infection, NK
clones, CD8
 
1
 
 T clones, or Jurkat T cells were infected with the
indicated FLAG-tagged recombinant vaccinia virus at an multi-
plicity of infection of 20:1 for 5 h (NK and T cell clones) or 10:1
for 2 h (Jurkat T cells). For experiments where NK cells were ac-
tivated by target cells, 5 
 
3
 
 10
 
6
 
 cloned NK cells were briefly pel-
leted with 2.5 
 
3
 
 10
 
6
 
 target cells and then incubated at 37
 
8
 
C for
the indicated period of time. In experiments involving specific
cell surface receptor cross-linking, the indicated quantity of cells
were incubated for 3 min on ice with anti-CD3 mAb OKT3 (1
 
m
 
g/ml) or anti-Fc
 
g
 
RIIIA mAb 3G8 (1 
 
m
 
g/ml). Washed cells
were then incubated with goat anti–mouse IgG F(ab
 
9
 
)
 
2
 
 at 37
 
8
 
C
for the indicated period of time. After stimulation, the cells were
lysed on ice for 10 min in 1 ml of buffer containing 20 mM Tris-
HCl, 40 mM NaCl, 5 mM EDTA, 50 mM NaF, 30 mM
Na
 
4
 
P
 
2
 
O
 
7
 
, 0.1% BSA, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM PMSF, 5 
 
m
 
g/ml
aprotinin, 10 
 
m
 
g/ml leupeptin, and 1% Triton X-100. Cellular
 
debris was removed by centrifugation at 14,000 rpm for 5 min at
4
 
8
 
C. Endogenous Vav and Vav-2 were immunoprecipitated from
the cell lysates for 1–2 h at 4
 
8
 
C using either anti-Vav or anti–
Vav-2.1 polyclonal rabbit antisera bound to protein A–Sepharose
beads. F.Vav-2 was immunoprecipitated from the lysate for 1–2 h
at 4
 
8
 
C using 1 
 
m
 
g of anti–FLAG-M2 mAb bound to goat anti–
mouse IgG–agarose beads. Protein complexes were washed four
times in wash buffer (lysis buffer lacking BSA). Bound proteins
were then eluted in 40 
 
m
 
l of SDS sample buffer, resolved by
SDS-PAGE, and transferred to Immobilon-P membranes (Milli-
pore). In some experiments, Vav and Vav-2 were detected using
specific anti-Vav and anti–Vav-2.2 polyclonal rabbit antisera fol-
lowed by protein A coupled to horseradish peroxidase (Amer-
sham Pharmacia Biotech) and the ECL detection system from
Amersham. Tyrosine-phosphorylated proteins were detected us-
ing the anti-pTYR mAb 4G10, and FLAG-tagged proteins were
detected using anti-FLAG mAb, M2 followed by sheep anti–
mouse IgG coupled to horseradish peroxidase and the ECL de-
tection system.
 
Results
 
Vav-2 Is Expressed in Cytotoxic Lymphocytes. 
 
Previous
Northern blot analysis has demonstrated that Vav-2 mes-
sage is present in the spleen and the thymus (16, 17), two
lymphoid organs rich in NK and T cells, respectively. We
therefore wanted to determine if Vav-2 protein is present
in cytotoxic lymphocytes. Analysis of the Vav-2 protein se-
quence identified several potential antigenic sites, and two
of them, amino acids 134–155 (TTENDDDVYRSLEE-
LADEHDLG) and amino acids 448–473 (EIIELLFHK-
MTDDPMNNKDVKKSHGK), were significantly differ-
ent in sequence from Vav. The synthesized peptides were
conjugated to KLH and used to generate the rabbit poly-
clonal Vav-2–specific sera, anti–Vav-2.1 and anti–Vav-2.2.
To demonstrate the specificity of the antisera, we infected
5 
 
3
 
 10
 
6
 
 Jurkat T cells with recombinant vaccinia virus ex-
pressing FLAG-tagged versions of either Vav (F.Vav) or
Vav-2 (F.Vav-2). After a 2-h infection, the recombinant
proteins were immunoprecipitated with normal rabbit se-
rum (NRS) or the antibodies indicated in Fig. 1 A, sepa-
rated by SDS-PAGE, and transferred to a nylon membrane.
As shown in Fig. 1 A, anti–Vav-2.1 sera immunoprecipi-
tates as much F.Vav-2 as the anti-FLAG mAb (Fig. 1 A,
top, compare anti–Vav-2.1 to anti-FLAG). In addition, the
anti–Vav-2.2 blotting antibody specifically reacts with
F.Vav-2 and not with F.Vav (Fig. 1 A, top). Lastly, the rab-
bit polyclonal anti-Vav sera is specific for Vav, as it did not
immunoprecipitate or Western blot Vav-2 protein (Fig. 1
A, bottom). These data demonstrate that the Vav-2 and
Vav polyclonal rabbit antisera are specific for their intended
proteins.
To determine if Vav-2 protein is present in hematopoi-
etic cells, we used the anti–Vav-2.1 sera to specifically im-
munoprecipitate endogenous Vav-2 from a series of lym-
phoid cells. We initially immunoprecipitated Vav-2 from a
limited number of cells (5 
 
3
 
 10
 
6
 
) but only observed a weak
band after Western blotting with the anti–Vav-2.2 sera.
This was in contrast to the amount of Vav protein that 
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could be detected after immunoprecipitation from the
same number of cells (data not shown). In fact, there is ap-
proximately three- to fourfold more Vav protein in NK
cells, as determined by either flow cytometry analysis of in-
tracellular staining or by immunoblotting (data not shown).
The low level of protein expression is consistent with pre-
vious Northern blot analysis demonstrating lower levels of
Vav-2 RNA in the thymus and spleen compared with Vav
RNA (17). However, when we immunoprecipitated Vav-2
from 25 
 
3
 
 10
 
6
 
 cells, Vav-2 protein was readily detectable
in not only the NK and CD8
 
1
 
 and CD4
 
1
 
 T cell clones,
but also in the 721 B lymphoblastoid cell line and the K562
erythroid cell line (Fig. 1 B). These data demonstrate that
Vav-2 protein is present in the various hematopoietic cell
types tested, albeit at a lower level than Vav.
 
Vav-2 Becomes Tyrosine Phosphorylated after FcR and TCR
Cross-Linking. 
 
Tyrosine phosphorylation of Vav and
Vav-2 is required for their functional activity (12, 13, 18).
It has been shown that Vav will undergo tyrosine phosphor-
ylation after cross-linking of activating receptors on he-
matopoietic cells. In addition, it has recently been shown
that both the Src and the Syk family PTKs can phosphory-
late Vav-2 in vitro (18). We therefore wanted to determine
if Vav-2 would undergo tyrosine phosphorylation after the
cross-linking of the Fc
 
g
 
RIIIA on NK clones and the TCR
on a CD8
 
1
 
 T cell clone. As indicated in Fig. 2 A, the NK
clone or a CD8
 
1
 
 T cell clone were left unstimulated or
stimulated through the FcR or TCR, respectively, over the
indicated time course. Endogenous Vav-2 protein was then
specifically immunoprecipitated using anti–Vav-2.1, sepa-
rated by SDS-PAGE, transferred to a nylon membrane, and
probed with anti-pTYR mAb 4G10. As can be seen in Fig.
2 A, cross-linking of either the FcR or the TCR results in
Vav-2 tyrosine phosphorylation (top panel). The tyrosine
phosphorylation of Vav-2 is rapid, peaking between 1 and
2 min of cross-linking and decreasing to background levels
by 10 min (Fig. 2 A, top). Tyrosine-phosphorylated pro-
teins migrating at the same size as Vav-2 were not evident
from FcR-stimulated NK cells immunoprecipitated with
protein A–Sepharose (Fig. 2 A, PAS, top), or with anti-
3BP2 peptide-purified polyclonal rabbit sera (anti-3BP2,
top). These results demonstrate that Vav-2 is coupled to
specific activating receptors on these two distinct lympho-
cyte populations.
Since it has been shown that different intracellular signals
can be required for the generation of antibody-dependent
cellular cytotoxicity (ADCC) and natural killing (28), we
wanted to determine if Vav-2 would become biochemi-
cally modified during the generation of natural cytotoxic-
ity. To do this, we infected NK clones with the F.Vav-2
recombinant vaccinia virus. This allows us to distinguish
Vav-2 protein derived from NK cells from that of the NK-
sensitive target cells, since both cell types express Vav-2
(Fig. 1 B). The F.Vav-2–infected NK clones were then in-
cubated with the erythroblastic leukemia cell line K562 for
the indicated time (Fig. 2 B), and the FLAG-tagged recom-
binant protein was then specifically immunoprecipitated
and analyzed for tyrosine phosphorylation. As shown in
Fig. 2 B, F.Vav-2 underwent tyrosine phosphorylation
during the generation of natural cytotoxicity against the
K562 cell line with tyrosine phosphorylation peaking be-
tween 1 and 5 min and decreasing to basal levels by 10
min. Similar results were obtained when F.Vav-2 tyrosine
phosphorylation was analyzed after the incubation of
F.Vav-2 recombinant vaccinia–infected NK clones with
the NK-sensitive C1R or 721 B lymphoblastoid target cell
lines (data not shown). These data indicate that Vav-2 is
linked to activating receptors on NK cells that initiate the
development of natural cytotoxicity toward these suscepti-
ble targets.
 
Vav-2 Enhances Cell-mediated Killing by Cytotoxic Lympho-
cytes. 
 
The above data identify Vav-2 as a signaling molecule
that is biochemically modified as a result of cross-linking of
Figure 1. The Vav-2 protein is present in hematopoietic cells. (A) Jur-
kat T cells (5 3 106) were infected with F.Vav or F.Vav-2 recombinant
vaccinia virus and then specifically immunoprecipitated with anti-FLAG
mAb (1 mg/ml), anti-Vav (10 mg/ml), or anti–Vav-2.1 (10 mg/ml) spe-
cific polyclonal rabbit antisera or NRS as a control. The immunoprecipi-
tates were resolved by SDS-PAGE, transferred to a nylon membrane, and
probed with either anti–Vav-2.2 polyclonal rabbit antisera (top, anti–
Vav-2.2) or anti-Vav polyclonal rabbit antisera (bottom, anti-Vav). This is
a representative example of three separate experiments. (B) Endogenous
Vav-2 was specifically immunoprecipitated from the indicated hemato-
poietic clones and cell lines (25 3 106) using the anti–Vav-2.1 polyclonal
rabbit sera or NRS as a control. The immunoprecipitates were resolved
by SDS-PAGE, transferred to a nylon membrane, and probed with anti–
Vav-2.2 polyclonal rabbit sera. This is a representative example of two in-
dependent experiments. 
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cell surface activating receptors on cytotoxic lympho-
cytes. To determine if Vav-2 influences cell-mediated
killing, we infected NK clones or a CD8
 
1
 
 T cell clone
with recombinant vaccinia virus expressing FLAG-tagged
versions of Vav-2, Vav as a positive control, or the parental
virus WR as a control for viral effect on killing. As previ-
ously noted (11), NK cells overexpressing Vav have
significantly enhanced killing of K562 target cells (Fig. 3,
NK/K562 compare WR to Vav). In addition, NK cells
overexpressing Vav-2 show comparable enhanced killing
toward the K562 target cell (Fig. 3, compare Vav and Vav-
2). The ability of Vav-2 to enhance natural cytotoxicity is
not restricted to killing of K562 target cells, since Vav-2–
overexpressing NK clones similarly enhance killing of both
the C1R and 721 B lymphoblastoid target cell lines (see
below and data not shown). Also, using reverse ADCC and
the FcR-bearing P815 target cell, we found that similar to
NK clones overexpressing Vav, Vav-2–overexpressing NK
clones increase killing initiated through the FcR (Fig. 3,
NK/P815 
 
1
 
 
 
a
 
-FcR). Importantly, Vav-2–overexpressing
NK cells and T cells did not kill P815 in the absence of the
appropriate stimulatory antibody or upon incubation with
an isotype-matched control antibody (data not shown).
Lastly, in a reverse ADCC using 
 
a
 
-CD3 mAb, we found
that killing by a CD8
 
1
 
 T cell clone was enhanced by over-
expression of Vav-2 to levels observed by Vav overexpres-
sion (Fig. 3, CD8
 
1
 
 T/P815 
 
1
 
 
 
a
 
-CD3). In addition, this
enhancement by Vav-2 was observed in other CTL lines
stimulated with 
 
a
 
-CD3 in a reverse ADCC assay, as well as
tumor-initiated killing by a melanoma-specific CTL (data
not shown). Taken together, these data suggest that Vav-2
is involved in the regulation of the cytolytic machinery
during the generation of natural killing and FcR-mediated
killing by NK clones and TCR-initiated killing by CD8
 
1
 
T cells.
 
The Vav-2 DH and SH2 Domains Are Required for En-
hanced Cellular Cytotoxicity. 
 
The above data indicate that
Vav-2 is involved in the regulation of cell-mediated killing
by cytotoxic lymphocytes. To determine what structural
features of Vav-2 are required for its function, we gener-
ated a series of inactivating point mutations (Fig. 4 A) and a
truncation mutant containing the Vav-2 PR–SH3–SH2–
SH3 domains (TRUNC; amino acids 574–878). Mutation
of highly conserved residues within the Vav DH domain
produce a protein lacking GEF activity (12, 29). To deter-
mine if Vav-2 GEF activity was required for enhanced cel-
lular cytotoxicity, we mutated the analogous residues in the
DH domain of Vav-2 (Fig. 4 A, Y213F/L217Q [Dbl
 
2
 
]).
Figure 2. Vav-2 is tyrosine phosphorylated after the cross-linking of
activating receptors on cytotoxic lymphocytes. (A) NK clones (25 3 106)
or a CD81 T cell clone (25 3 106) was stimulated with anti-FcR mAb
3G8 (1 mg/ml) or anti-CD3 mAb OKT3 (1 mg/ml) over the indicated
time course. After the stimulation, Vav-2 was specifically immunoprecip-
itated with anti–Vav-2.1 rabbit polyclonal sera. As negative controls,
stimulated cell lysates were immunoprecipitated with an irrelevant pep-
tide-purified polyclonal rabbit antibody (anti-3BP2) or protein A–Seph-
arose alone (PAS). The immunoprecipitates were resolved by SDS-
PAGE, transferred to a nylon membrane, and probed with either anti-
pTYR mAb 4G10 (top) or anti–Vav-2.2 polyclonal rabbit sera (bottom).
(B) NK clones (5 3 106) were infected with F.Vav-2 recombinant vac-
cinia virus for 5 h. After the infection, the cells were incubated with 2.5 3
106 NK-sensitive K562 target cells for the indicated time, and then
F.Vav-2 was specifically immunoprecipitated from the infected NK clone
using anti-FLAG mAb. The immunoprecipitates were resolved by SDS-
PAGE, transferred to a nylon membrane, and probed with either anti-
pTYR mAb 4G10 (top) or anti-FLAG mAb (bottom).
Figure 3. Overexpression of Vav-2 enhances killing of cytotoxic lym-
phocytes. NK clones (2 3 106) and CD81 T cell clones (106) were in-
fected with the indicated recombinant vaccinia virus. The infected NK
clones were then incubated with either 51Cr-labeled K562 cells (NK 1
K562) or 51Cr-labeled P815 cells coated with 0.15 mg/ml of the anti-
FcR mAb 3G8 (NK/P815 1 anti-FcR). The infected CD81 T cell
clones were incubated with 51Cr-labeled P815 cells coated with 0.15 mg/
ml of anti-CD3 mAb OKT3 (CD81 T/P815 1 anti-CD3). The data are
expressed as lytic units. Data shown is representative of four separate ex-
periments.386 Vav-2 Regulates Cellular Cytotoxicity
We then infected NK clones with recombinant vaccinia
encoding wild-type F.Vav-2 or the Dbl2 mutant and mea-
sured their cytolytic potential. As shown in Fig. 4 B, over-
expression of Vav-2 in NK clones results in enhancement
of both forms of cellular cytotoxicity, whereas overexpres-
sion of the Dbl2 mutant does not. The inability of the
Dbl2 mutant to enhance killing is not due to the level of
expression of the recombinant protein, as both Vav-2 and
the Dbl2 mutant are expressed to similar levels (Fig. 4 B,
inset, compare lanes 2 and 4). These data suggest that a
functional DH domain is required for Vav-2 enhancement
of cellular cytotoxicity.
Tyrosine phosphorylation of Vav family members is re-
quired for GEF activity. The ability of Vav to couple to ac-
tivating receptors and undergo receptor-initiated tyrosine
phosphorylation requires an intact SH2 domain (14, 15).
To determine if the SH2 domain of Vav-2 is required for
its ability to couple to activating receptors in NK cells, we
generated an inactivating mutation in the highly conserved
FLVR sequence of the Vav-2 SH2 domain (Fig. 4 A,
R698A). We subsequently infected NK clones with
FLAG-tagged versions of wild-type Vav-2 or the R698A
mutant and measured tyrosine phosphorylation after FcR
cross-linking. As shown in Fig. 4 C, in contrast to wild-
type Vav-2, the R698A mutant does not undergo tyrosine
phosphorylation after cross-linking of the FcR on NK
cells, indicating that a functional SH2 domain is required
for its ability to couple to the FcR. The R698A mutant
was also unable to couple to activating receptors during the
generation of natural cytotoxicity toward the K562 or 721
target cell lines, or after TCR cross-linking on a CD81 T
cell clone (data not shown). As expected, overexpression of
the R698A mutant in NK clones does not result in en-
hanced natural cytotoxicity or FcR-initiated killing (Fig. 4
B, compare Vav-2 to R698A). The R698A mutant was
also unable to enhance TCR-initiated killing by a CD81 T
cell clone (data not shown). These data indicate that the
SH2 domain of Vav-2 is required for its ability to link to
activating receptors and undergo tyrosine phosphorylation.
It has been demonstrated that overexpression of a trun-
cated version of Vav, Vav-C, that contains the COOH-
terminal SH2 and SH3 domains could inhibit Vav-regu-
Figure 4. The Vav-2 Dbl homol-
ogy and SH2 domains are required for
enhanced cellular cytotoxicity. (A)
The human Vav-2 protooncogene is
an 878–amino acid protein that has a
number of complex structural do-
mains, including a calponin homology
(CH), acidic (AR), Dbl homology
(Dbl), pleckstrin homology (PH), cys-
teine-rich (CR), proline-rich (PR),
SH3, and SH2 domains. Wild-type
Vav-2 is schematically depicted in the
top line of this figure (Vav-2). The
mutants used in this study include: the
inactivating Dbl homology domain
mutant Y213F/L217Q (Dbl2), the in-
activating W503L PH domain mu-
tant, and an inactivating SH2 domain
mutant R698A. In addition, a truncated version of Vav-2 was produced that contains the PR–SH3–SH2–SH3 domains (TRUNC). All mutants contain
an NH2-terminal FLAG epitope. (B and D) NK clones (2 3 106) were infected with the indicated recombinant vaccinia virus. Cellular cytotoxicity of
the infected NK clones was assayed as described in Fig. 3. The levels of recombinant protein were determined by Western blot of whole cell lysates pre-
pared from infected NK clones (106). The data are expressed as lytic units. Data shown is representative of six separate experiments. (C) NK clones (5 3
106) were infected with the indicated recombinant vaccinia virus, stimulated with anti-FcR mAb 3G8 (1 mg/ml) at 378C over the indicated time course,
and then specifically immunoprecipitated with anti-FLAG mAb (1 mg/ml). The immunoprecipitates were resolved by SDS-PAGE, transferred to a ny-
lon membrane, and probed with either antiphosphotyrosine mAb 4G10 (top, anti-pTYR) or anti-FLAG mAb (bottom, anti-FLAG). This is a represen-
tative example of three separate experiments. 387 Billadeau et al.
lated NFAT–AP-1–mediated gene transcription (15). These
data suggest that the SH2 domain of Vav plays a significant
role in the regulation of Vav activation after receptor cross-
linking. We therefore wanted to determine if a similar mu-
tant of Vav-2 (Fig. 4 A, TRUNC) would antagonize cell-
mediated killing. As shown in Fig. 4 D, NK cell–mediated
cellular cytotoxicity can be inhibited by overexpression of
the truncation mutant of Vav-2. The ability of the Vav-2
TRUNC mutant to inhibit cell-mediated killing requires a
functional SH2 domain, as an inactivating mutation
(R698A) in the TRUNC mutant reverses its inhibitory ef-
fect (data not shown). Interestingly, although the Vav-C
truncation mutant undergoes TCR-mediated tyrosine
phosphorylation, the Vav-2 TRUNC mutant does not be-
come tyrosine phosphorylated after FcR or TCR cross-
linking (data not shown). Therefore, in contrast to Vav,
potential tyrosine phosphorylation sites are not present in
the COOH terminus of Vav-2.
The PH Domain Is Important in the Activation of Vav-2
from Some but Not All NK Cell Activating Receptors.  It
was previously suggested that the PH domain is required
for Vav tyrosine phosphorylation and GEF activity (30).
Interestingly, mutation of the Vav-3 PH domain had no
effect on its GEF activity (31). We therefore mutated a
highly conserved tryptophan in the Vav-2 PH domain in
an attempt to determine the role of this domain in regulat-
ing Vav-2 tyrosine phosphorylation and activity during the
generation of cell-mediated killing (Fig. 4 A, W503L).
This mutation has been shown to inactivate the PH do-
main of other Rho and Rac GEFs (31, 32). We initially
analyzed the W503L mutants ability to couple to activating
receptors in cytotoxic lymphocytes. Interestingly, we
found no difference in the level or duration of receptor-
mediated tyrosine phosphorylation of Vav-2 or the W503L
mutant after FcR or target stimulation of NK clones or af-
ter TCR cross-linking in the CD81 T cell clone (data not
shown). However, it remained possible that qualitative dif-
ferences in tyrosine phosphorylation or localization of the
protein might impact on Vav-2 function. As shown in Fig.
5, overexpression of the W503L mutant in NK clones re-
sults in enhanced killing of the K562 target cell line, but
natural cytotoxicity toward the 721 B lymphoblastoid cell
line was not similarly enhanced (Fig. 5, compare NK 1
K562 to NK 1 721). In addition, the W503L mutant was
unable to enhance killing initiated through the NK FcR or
TCR-initiated killing by a CD81 T cell clone (Fig. 5,
NK/P815  1 a-FcR, and data not shown). In fact, overex-
pression of the W503L mutant consistently inhibited kill-
ing to below that observed by WR, indicating that this
mutant functions as a dominant negative (Fig. 5, compare
WR to W503L). These data suggest that the PH domain is
required for Vav-2 enhancement of cell-mediated killing
after engagement of certain activating receptors on cyto-
toxic lymphocytes but not others.
Vav-2 Does Not Activate NFAT–AP-1–mediated Gene
Transcription after TCR Cross-Linking.  Previous studies
have focused on a significant role for Vav in the regulation
of the NFAT–AP-1 response element in the IL-2 promoter
after TCR cross-linking (33, 34). We therefore tested
whether Vav-2 could regulate the IL-2 promoter after
TCR cross-linking. Jurkat T cells were electroporated with
a control vector, FLAG-tagged Vav expression vector, or
Vav-2 expression vector along with an NFAT–AP-1 lu-
ciferase reporter construct. After an overnight incubation,
the cells were stimulated as indicated in Fig. 6 A, and lu-
ciferase activity was measured and is expressed as the per-
cent maximal NFAT–AP-1 response. As can be seen in
Fig. 6 A, overexpression of Vav in Jurkat T cells results in
increased levels of NFAT–AP-1 activity after anti-CD3
and anti-CD3 1 PMA stimulation. However, overexpres-
sion of Vav-2 had no significant effect on the levels of
NFAT–AP-1 activation under any stimulation conditions
(Fig. 6 A, compare Vav to Vav-2). The inability of Vav-2
to regulate the NFAT–AP-1 response was not due to levels
of expression of recombinant protein, as both Vav and
Vav-2 were expressed at similar levels (Fig. 6 A, inset). In
addition, compared with Vav, Vav-2 underwent similar ki-
netics of tyrosine phosphorylation in Jurkat T cells after
TCR cross-linking (data not shown).
Activation of NFAT Requires a Sustained Level of Intra-
cellular Ca21 after TCR Engagement. It has recently been
found that Vav is involved in the regulation of intracellular
Ca21 after TCR engagement (27, 35). One possible reason
for the inability of Vav-2 to regulate NFAT–AP-1–medi-
ated gene transcription is that it cannot regulate intracellu-
lar Ca21 levels after TCR engagement. Indeed, as shown in
Fig. 6 B, TCR cross-linking of Indo-1–loaded Jurkat T
cells overexpressing Vav leads to a sustained level of intra-
cellular Ca21 over the duration of the assay compared with
the control-infected population (Fig. 6 B, compare Vav to
WR). However, whereas Vav-2–overexpressing cells dem-
onstrate an initial increase in intracellular Ca21 after TCR
engagement compared with control infected cells, the sus-
tained response is diminished compared with Vav-express-
Figure 5. The Vav-2 PH domain is required for enhanced cell-medi-
ated killing after stimulation through some, but not all activating recep-
tors. NK clones (2 3 106) were infected with the indicated recombinant
vaccinia virus (inset). Cellular cytotoxicity of the infected NK clones was
assayed as described in Fig. 3. In addition to K562, natural cytotoxicity
toward the B lymphoblastoid cell line 721 was also assessed. The levels of
recombinant protein were determined by Western blot of whole cell ly-
sates prepared from infected NK clones (106). The data are expressed as
lytic units. Data shown is representative of four separate experiments.388 Vav-2 Regulates Cellular Cytotoxicity
ing cells (Fig. 6 B, compare Vav to Vav-2). Although Vav-2
overexpression does not lead to sustained levels of intra-
cellular Ca21 after TCR engagement, its inability to regulate
the NFAT–AP-1 response element of the IL-2 promoter
may be due in part to its activation of different Rho family
proteins compared with those activated by Vav. Taken to-
gether, these data suggest that Vav-2 does not impact
NFAT–AP-1–mediated gene transcription after TCR cross-
linking.
Discussion
The Rac and Rho families of GTPases are intimately in-
volved in the regulation of various hematopoietic cell ef-
fector functions, including gene transcription, phagocyto-
sis, and the development of cell-mediated killing (1, 11, 36,
37). Previous genetic and pharmacologic approaches have
demonstrated that RhoA is a critical regulator of cell-medi-
ated killing by cytotoxic lymphocytes (11, 23). It is clear
that Vav plays a critical role in the regulation of Rac family
effector functions downstream of activating receptors on
lymphocytes (38, 39), including NK cells (11, 22). How-
ever, a specific Rho family GEF has not been identified
that links activating receptors on cytotoxic lymphocytes to
Rho-regulated effector functions. In this study, we have
identified that Vav-2 is expressed in various hematopoietic
cells, including NK cells and T cells, and have shown for
the first time that Vav-2 is coupled to activating receptors
on cytotoxic lymphocytes. Furthermore, we found that
overexpression of Vav-2 in cytotoxic lymphocytes results
in increased cell-mediated killing of susceptible targets. In
addition, Vav-2 GEF activity toward Rho family GTPases
is required for its ability to enhance cellular cytotoxicity,
since an inactivating DH mutant was unable to enhance
killing (Fig. 4 B, Dbl2). Taken together, these data high-
light a role for the Vav-2 GEF in the generation of cell-
mediated killing by cytotoxic lymphocytes.
Many proteins, in particular those with enzymatic func-
tion, when overexpressed in an inactive form function as
dominant negatives by presumably linking to their appro-
priate upstream signaling cascades and inhibiting down-
stream signals. It is interesting that neither the Vav-2 GEF
inactive mutant (Dbl2) nor a similar Dbl-inactivating Vav
mutant function as dominant negatives even though the
mutant protein is still capable of undergoing receptor-initi-
ated tyrosine phosphorylation, implying that it is recruited
to the activating receptor complex (data not shown). Al-
though it has been shown that point mutations or small de-
letions within the Dbl domain result in the loss of GEF ac-
tivity, it is not clear if this is due to a lack of interaction of
the GEF with its respective GTP-binding protein or de-
creased GEF activity toward bound GTPases (12, 29, 32).
Therefore, if the Vav-2 Dbl2 protein was still recruited to
the receptor complex but fails to interact with its target
GTPases, then endogenously activated GEFs could still
function to regulate their respective GTP-binding proteins.
Further studies will be required to elucidate the mechanism
by which mutation of the Vav family Dbl domain influ-
ences its GEF activity.
It was previously demonstrated in vitro that both Src and
Syk family PTKs can phosphorylate Vav-2 and that this ty-
rosine phosphorylation was required for Vav-2 GEF func-
tional activity (12, 13). In this study, we demonstrate that
Vav-2 becomes tyrosine phosphorylated after FcR and
Figure 6. Vav-2 does not regulate the IL-2 promoter after TCR cross-
linking. (A) Jurkat T cells (107) were electroporated with 10 mg of an
NF-AT/AP-1.luciferase reporter construct and 20 mg of the indicated
regulatory plasmids. Both Vav and Vav-2 constructs contain an NH2-ter-
minal eight–amino acid FLAG epitope. After an overnight rest, the cells
were either left unstimulated or stimulated for 6 h with anti-CD3 mAb
OKT3 (1 mg/ml), a combination of anti-CD3 (1 mg/ml) and PMA (20
ng/ml), or a combination of PMA (20 ng/ml) and ionomycin (2 mM).
Cells were then harvested and assayed for luciferase activity as described
in Materials and Methods. The data are presented as the percentage of
maximal NFAT–AP-1 activity obtained by stimulation with PMA 1 ion-
omycin. Maximum NFAT–AP-1 responses did not vary significantly be-
tween transfected samples. (Top left insets) Protein expression in the
transfected cells was verified by immunoprecipitation of 2 3 106 elec-
troporated cells with anti-FLAG mAb (1 mg/ml), followed by immuno-
blotting with the same antibody. The data shown is representative of three
separate experiments. (B) Jurkat T cells (5 3 106) were infected with
nonrecombinant vaccinia (WR) or recombinant vaccinia expressing Vav
or Vav-2. After infection, the cells were loaded with Indo-1 (5 mM), di-
vided in half, and treated with goat anti–mouse IgG F(ab9)2 alone or stim-
ulated with a combination of anti-CD3 (2.5 mg/ml) and goat anti–mouse
IgG F(ab9)2. The samples were immediately analyzed by flow cytometry
over the indicated time course. The data from the anti-CD3– and goat
anti–mouse IgG F(ab9)2–stimulated cells is shown. Goat anti–mouse IgG
F(ab9)2 treated cells did not demonstrate Ca21 fluxes in the absence of
anti-CD3 mAb (data not shown). This is a representative example of four
separate experiments.389 Billadeau et al.
TCR cross-linking on NK cells and T cells, respectively,
and during the development of natural killing. However,
the specific Src or Syk family protein tyrosine kinase(s) that
mediate Vav-2 tyrosine phosphorylation downstream of
these activating receptors remains to be identified. The
SH2 domain of Vav is required for its ability to couple to
activating receptors and carry out Vav-regulated effector
functions (14, 15). Clearly, the ability of Vav-2 to regulate
cell-mediated killing downstream of these activating recep-
tors requires a functional SH2 domain, since inactivation of
the SH2 domain uncouples Vav-2 from receptor-mediated
tyrosine phosphorylation and the generation of cell-medi-
ated killing (Fig. 4, B and C). The inability of this mutant
to function as a dominant negative is most likely due to
lack of recruitment to the activating receptors, where it
would putatively interact not only with its downstream
GTP-binding proteins but potentially other cell signaling
molecules. Indeed, Vav has been shown to interact with
numerous growth factor receptors upon ligand engagement
and also with numerous signaling molecules that undergo
tyrosine phosphorylation after receptor cross-linking (5, 6,
38, 39). SH2 domains contain highly conserved phospho-
tyrosine binding residues and variable residues that mediate
binding to the side chains of amino acids that flank the
phosphotyrosine (40). The SH2 domain–containing pro-
teins can be grouped on the basis of these variable residues,
and the presence of a threonine at the bD5 position of the
Vav SH2 domain places it in group II, possessing specificity
toward pYMEP-containing peptides (41, 42). Interestingly,
neither Vav-2 nor Vav-3 encode a threonine at this posi-
tion. Therefore, determining whether the Vav, Vav-2, or
Vav-3 SH2 domains interact with distinct or an overlap-
ping set of tyrosine-phosphorylated proteins will provide
insight into how this family of proteins is regulated.
The overexpression of a truncated version of Vav con-
taining the COOH-terminal SH2 and SH3 domains, Vav-C,
was found to block TCR-mediated, NFAT–AP-1–medi-
ated gene transcription (15). However, a mutant Vav-C,
Vav-CSH2RK, containing an inactivating mutation in the
SH2 domain could not similarly suppress NFAT–AP-1
gene transcription, suggesting that the Vav SH2 domain
must serve to couple Vav to upstream TCR-initiated signals.
Similarly, we have found that a Vav-2 truncation mutant
containing the COOH-terminal PR–SH3–SH2–SH3 do-
mains (TRUNC; Fig. 4 D, compare Vav-2 to TRUNC),
but not a TRUNC mutant carrying an SH2 inactivating
mutation, inhibits cell-mediated killing when overex-
pressed in cytotoxic lymphocytes (our unpublished obser-
vation). Interestingly, although the Vav-C mutant under-
went tyrosine phosphorylation after TCR cross-linking
(15), we have not observed tyrosine phosphorylation of the
Vav-2 TRUNC mutant after FcR or TCR cross-linking
(data not shown). This suggests that in contrast to Vav,
Vav-2 contains no tyrosine within this domain that become
phosphorylated after cross-linking of these specific recep-
tors. We are currently investigating whether the Vav-2
TRUNC mutant functions as a dominant negative by an-
tagonizing Vav-2 tyrosine phosphorylation or by prevent-
ing recruitment to areas of activation during the generation
of cell-mediated killing.
The PH domains of numerous proteins have been
shown to interact with membrane phospholipids generated
by phosphatidyl inositol 3-kinase (PI3-K; reference 43). In-
terestingly, all Dbl family proteins have the characteristic of
a DH domain followed by a PH domain (2). This con-
served structural architecture within the Dbl family of pro-
teins suggests that these two domains have important roles
in the regulation of their activity. However, the role that
the PH domain plays in the regulation of GEF activity
among the various Dbl family members appears to be pro-
tein specific. For instance, it has been shown that deletion
or mutation of the PH domains of Dbl, Vav-3, or onco-
Lbc does not impair their intrinsic GEF activity (31, 32,
44). However, it was recently shown in vitro that the Vav
PH domain interacts with PI3-K–generated phospholipids,
and that this interaction is required for not only protein ty-
rosine kinase–mediated tyrosine phosphorylation of Vav
but also its GEF activity (30). Interestingly, the W503L PH
domain mutant of Vav-2 behaves similarly to a deletion
mutant of Vav (27) in that it enhances killing through some
but not all activating receptors on NK cells and T cells. We
have previously shown that treatment of NK cells with
wortmannin, a drug that inhibits PI3-K activity, decreased
FcR-mediated but not natural killing of the K562 target
cell line (28). Moreover, initial experiments have suggested
that NK cells treated with wortmannin have decreased cy-
totoxicity toward 721 target cells (data not shown). It is
therefore possible that certain activating receptors (TCR,
FcR, and those that mediate killing of 721 cells) rely on the
generation of membrane phospholipids by PI3-K for the
subsequent recruitment and compartmentalization of PH
domain–containing molecules required for the generation
of specific effector functions. We are currently investigating
the role that the Vav and Vav-2 PH domains have in tar-
geting these molecules to the correct compartment during
lymphocyte activation.
It is well known that Vav plays a significant role in the
regulation of T cells after TCR cross-linking (45). Most
importantly, Vav has been shown to be a potent regulator
of the NFAT–AP-1 transcription complex within the IL-2
promoter (33, 34). In contrast to Vav, we found that over-
expression of Vav-2 in the Jurkat T cell line did not result
in enhanced NFAT–AP-1–mediated gene transcription af-
ter TCR cross-linking (Fig. 6 A). Recently, using thy-
mocytes from Vav-deficient mice, it was found that Vav
plays a significant role in the regulation of intracellular Ca21
after TCR cross-linking (35). Sustained levels of intracellu-
lar Ca21 are required for the activation of the phosphatase
calcineurin. Upon activation, calcineurin dephosphorylates
cytoplasmic NFAT, resulting in nuclear localization and ac-
cumulation of NFAT (46). We have recently shown that
the CH domain of Vav is important in regulating the in-
crease in intracellular Ca21 after TCR cross-linking in the
Jurkat T cell (27). As shown in Fig. 6 B, compared with
Vav, Vav-2 does not lead to sustained levels of intracellular
Ca21 after TCR cross-linking of Indo-1–loaded Jurkat T390 Vav-2 Regulates Cellular Cytotoxicity
cells. One possible reason for this is that the CH domains of
Vav and Vav-2, although homologous, have different regu-
latory functions. Consistent with this is the observation that
although partial deletion of the CH domain of Vav pro-
duces an oncogenic protein, truncation of both the CH and
acidic regions of Vav-2 is required for production of an on-
cogenic protein (18). However, the fact that Vav and Vav-2
regulate distinct Rac and Rho family members may also
be a reason why Vav, but not Vav-2, regulates NFAT–AP-
1–mediated gene transcription.
It was recently found that a constitutively active mutant
of Rho, V14Rho could synergize with PMA in the regula-
tion of an isolated AP-1 response element from the IL-2
promoter (47). Interestingly, V14Rho did not regulate the
transcriptional activity of luciferase reporter constructs con-
taining isolated NFAT–AP-1, Oct-1, or nuclear factor kB
response elements (47). Furthermore, inactivation of Rho
by overexpression of C3 exoenzyme in the thymus results
in a small thymus and decreased cellularity (48). It has also
been shown that Rho is important for the survival of pre-T
cells and regulates their cell cycle progression (49). There-
fore, it is possible that the Rho family GEF Vav-2 plays a
significant role downstream of activating receptors in ma-
turing T cells, resulting in the activation of Rho family
members and their downstream signaling cascades.
In this study, we have shown for the first time that Vav-2
protein is present in hematopoietic cells and that it un-
dergoes receptor-mediated tyrosine phosphorylation after
cross-linking of activating receptors on NK and T cells. In
addition, we have shown that Vav-2 plays a significant role
in the regulation of cell-mediated killing by cytotoxic lym-
phocytes. Clearly, identifying molecules that interact with
Vav-2 and determining the role that Vav-2 has in the regu-
lation of other hematopoietic cells will be an important
step toward understanding this new member of the Vav
family of GEFs.
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